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In this study new free-trade agreements are discussed, which are based on 
the breaking down of tariff and technical barriers and normally exclude 
most of the poorest countries in the world. Considering the current context 
of economic globalization and its health impacts, seven controversial points 
of these treaties and their possible implications for global public health are 
presented, mainly regarding health equity and other health determinants. 
Finally, this research proposes a greater social and health professionals 
participation in the formulation and discussion of these treaties, and a deeper 
insertion of Brazil in this important international agenda.
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International trade demonstrates the increased 
spatial interdependence between the global econo-
mies: immense flows of capitals, goods, raw mate-
rials, services, and people are part of a new stage 
of globalization.
Trade deals, today, are different from those made in 
previous decades, which were focused on lowering 
tariffs to decrease prices of goods for consumers and, 
at the same time, were based on products adapted to 
their environments.
Nowadays, massive international trade can be a disrup-
tive economic and social force, as it changes the condi-
tions in which wealth is distributed within nations and 
economies, due to changes it causes in prices of prod-
ucts, in employment rates, wages, social and environ-
mental conditions.2 Whole economic regions might be 
disrupted by a massive import trade, with consequent 
unemployment, ill-health, and suffering.
Another important point is that, currently, most of trade 
flows concern corporations exchanging parts and goods 
with other corporations, or within the same corpora-
tion. Nations are the unit used to record accounts of 
trade flows crossing borders, but 30.0% to 50.0% of 
international trade concern exchange of goods of the 
same multinational corporation.2 These numbers indi-
cate that global trade became an intra-industrial struc-
ture of exchange, favored by the emergence of global 
supply chain. So, free-trade agreements benefit mainly 
large corporations.
Prior to 1970s, there was a dichotomy between devel-
oped economies (that sold mainly finished goods) and 
developing economies (that sold mainly raw mate-
rials). This situation changed as industrial devel-
opment took place in many developing economies 
in Latin America, Southeast Asia, and East Asia. 
Most industrial processes that initially took place 
in developed economies were relocated to devel-
oping countries, with lower production costs, namely 
due to cheaper labor, proximity to raw material and 
expanding markets, lower environmental standards 
and tax rebates, but, at the same time, providing better 
paid jobs for their population. 
The aim of this article was to discuss some side 
effects of this process, mainly on public health and 
its determinants that have not been studied in all their 
complexity and need to be better discussed among 
health professionals.
INTRODUCTION
Trade agreements and related health issues
New three controversial free-trade agreements are 
under negotiations: 
• Canada-European Union Comprehensive Economic 
and Trade Agreement (CETA), 
• Transatlantic Trade and Investment Partnership 
(TTIP),a between European Union and United 
States of America, 
• Trans-Pacific Partnership Agreement (TPP), between 
Australia, Brunei, Darussalam, Canada, Chile, Japan, 
Malaysia, Mexico, New Zealand, Peru, Singapore, 
the United States, and Vietnam.
These three free-trade agreements represent a new inter-
national context.3
The USA and European Union represent 800 million 
people of the world’s most affluent market. 
Reading the documents of those agreements one iden-
tifies that they aim at open new markets for goods (in 
special pharmaceutical and food products, regarding 
health issues), to create jobs and opportunities, to save 
money for corporations and avoid tariff and non-tariff 
barriers. The following phrase extracted from a TTIPb 
document illustrates well this issue: “It could result in 
millions of euros of savings to companies and create 
hundreds of thousands of jobs”.
Most developed countries have equivalent set of technical 
requirements for medical equipment that are necessary for 
human safety, and might develop mutual recognition of 
health professional qualifications. So non-tariff barriers 
should not be a large problem for them. Moreover, agri-
cultural subsidies will not be permitted by those treaties. 
The documents highlight the idea that treaties will be 
beneficial to every country. Why then these free-trade 
agreements have been receiving so many criticisms and 
motivating public demonstrations in cities like New 
York, Tokyo, and in countries such as Australiab and New 
Zealand? Why the demonstrations focus on the impacts on 
public health? Why Global Health Academic Congresses 
have been organizing discussions on these treaties?
Global health impacts
Based on the text about these treaties and discussions in 
the Internet, I point out and discuss some controversial 
points related to those free-trade agreements, from the 
a European Commission. Transatlantic Trade and Investment Partnership (TTIP). [cited 2014 Sept 29]. Available from: http://ec.europa.eu/trade/
policy/in-focus/ttip/about-ttip/
b Protecting the health of the Australians in the TPPA: press release Public Health Association. [cited 2014 Sept 29]. Available from: http://
www.itsourfuture.org.nz/protecting-the-health-of-australians-in-the-tppa/
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point of view of Latin America, even though only few 
Latin American countries participate in the negotiations 
of these agreements (Mexico, Peru, and Chile are in the 
TPP), having a global health perspective as theoretical 
background. For this, I start quoting Kickbusch, in the 
article “Global Health: a definition”.
“Global Health focus is the impact of global interde-
pendence on the determinants of health, the transfer 
of health risks, and the policy response of countries, 
international organizations and the many other actors 
in the global health arena. Its goal is the equitable 
access to health in all regions of the globe”.c 
The idea of reinforcing trade and its benefits among 
the richest economies of the world show that equitable 
access to health is out of the agenda of the international 
trade policies of these countries. Trade agreements 
exclude most developing nations, with very poor health 
conditions, as African and Caribbean nations, that will 
keep facing tariff and non-tariff barriers for the sale of 
their products. Thus, the economic and social devel-
opment of these poorest nations will be impaired by 
such barriers and, consequently, health accessibility 
will never be equitable around the globe.
Additionally, new intellectual property rules for the 
treaties (mainly the TPP) will grant pharmaceutical 
companies longer-term monopolies on new medica-
tions. As a result, companies could charge high prices 
without competing with generic providers. Some public 
health experts have warned it would result in higher 
prices around the world and lack of access to life-saving 
drugs in poor countries.4 In addition, a document deliv-
ered by UNITAID Secretariat, from the World Health 
Organization, called “The Trans-Pacific Partnership 
Agreement: implications for access to Medicines and 
Public Health”, published in 2014, warns on the higher 
prices of pharmaceutical products for HIV treatment 
due to the TPP: 
“The impact of generic entry on the prices of medi-
cines can be significant. This has been most drama-
tically demonstrated in the case of HIV medicines. 
In 2001, the price available from originator com-
panies for the first-line triple combination of anti-
retroviral, was $10,439 per person per year, while 
generic companies were able to offer a price of $350 
per person per year”.5 
Impact assessments of pharmaceutical patent and 
medical device term extensions in various countries indi-
cate significant increases in health spending for govern-
ments and for people. There is also the risk of some 
infectious diseases as tuberculosis getting out of control, 
and of a regression in the control of many other diseases 
as asthma, circulatory diseases, cancer, and diabetes. 
Also, there is new corporate empowerment in these 
treaties, which would allow foreign companies to chal-
lenge laws or regulations in a privately run international 
court. Until now, under World Trade Organization trea-
ties, this political power to contest government law is 
reserved for sovereign nations. With the new treaties, 
corporations will have the power to contest laws in other 
countries as mentioned by Stiglitzd in 2014. 
These two provisions (longer term monopoly and private 
run international court) – from the point of view of 
Brazil, although Brazil has not signed and is not part of 
these agreements – would jeopardize the most successful 
program in the world against HIV/AIDS, as it was based 
on the breaking of patents for Public Health reasons, and 
on the free distribution of medicines for infected patients.
The Brazilian Unified Health System (SUS) also distrib-
utes free of charge medicines to prevent noninfectious 
diseases, as high blood pressure, diabetes, asthma, and 
cancer, among others. This distribution would have outra-
geous costs if Brazil signed those treaties. The increase 
in the price of medicines and medical devices is the main 
worry behind the protests in Australia and Japan. Even in 
the United States, the fight to lower the cost of health care 
will be affected by these noxious provisions, according to 
the article by Stiglitz,d in 2014, in The New York Times. 
However, these provisions, which protect and benefit 
corporations that invest in research and patent, are 
very different regarding protection of natural resources 
and cultural knowledge for what we read in the 
Environment Chapter of TPP, recently disclosed by 
Wikileaks.e In these two cases, the text emphasizes 
the sharing of benefits. I mention one part of the docu-
ment, as it might affect Latin American countries that 
have indigenous populations (Mexico, Chile and Peru):
“The parties are committed to:
Promoting and encouraging the conservation and 
sustainable use of biological diversity and sharing 
in a fair and equitable way the benefits arising from 
the utilization of genetic resources. 
Respecting, preserving and maintaining the know-
ledge, innovations, and practices of indigenous and 
local communities embodying traditional lifestyles 
relevant for the conservation and sustainable use of 
biological diversity, and encourage the equitable 
c Kickbusch I. Global health: a definition. New Haven: Yale University; 2002 [cited 2013 Jan 21]. Available from: http://www.ilonakickbusch.
com/kickbusch-wAssets/docs/global-health.pdf 
d  Stiglitz JE. The great divide: on the wrong side of globalization. New York Times [Internet]. 2014 Mar 15 [cited 2014 Oct 3]; The Opinion 
Pages. Available from: http://opinionator.blogs.nytimes.com/2014/03/15/on-the-wrong-side-of-globalization/
e WikiLeaks. Secret Trans-Pacific Agreement (TPP): Environment chapter. 2013 [cited 2014 Jan 15]. Available from: https://wikileaks.org/tpp-
enviro/pressrelease.html
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sharing of the benefits arising from the utilization 
of such knowledge.”
Another important issue regarding public health is that 
the treaties will change the food system, according to 
Friel,1 in Latin America and probably in the Eastern 
countries by:
• Opening of domestic markets towards internatio-
nal food trade;
• Subsequent increased entry of transnational food 
companies and their global market;
• Global food advertising (cultural hybridization); 
• Food industries will have access to a large market 
in developing and in Eastern countries, where 
highly-processed food is not as widespread, with 
a large impact on obesity and noncommunicable 
diseases, by altering local availability, nutritional 
quality, price and desirability of food.
The best example is the case of Mexico under North 
American Free Trade Agreement (NAFTA): trade liberal-
ization has resulted in disproportionately large increases 
in imports and in domestic production of processed 
foods, skewing the food supply towards an oversupply 
of highly processed foods, that is, calorie-rich and 
nutrient-poor foods, increasing the risk of noncommu-
nicable diseases with an epidemics of obesity. Mexico 
has the second largest proportion of obese people in the 
world (30.0%), after the US, and is followed by Chile.
A greater increase in international trade will also have 
tremendous impact on environmental health world-
wide, as both maritime and air freight transportation 
depend on petroleum. The increase in international trade 
proposed by the new trade agreements will contribute 
to the expected scarcity of this fossil fuel, and to foster 
pollution derived from its use. Regarding environmental 
protection, contrary to the proposed increase, a rational-
ization of international trade and its underlying supply 
chains should be put in practice, as environmental issues, 
especially climate change, are becoming more important. 
Consequently one can observes a growing need to regu-
late components of international trade that have nega-
tive externalities, as CO2 emissions in the case of fossil 
fuels, and consequent health effects. 
International trade enables several countries to mask their 
energy consumption and pollutant emissions by importing 
goods that are produced elsewhere, where environmental 
and health externalities are generated. Thus, international 
trade permits a shift in the international division of produc-
tion, but also a division between the generation of envi-
ronmental health externalities, with a heavier burden for 
developing nations that usually have weaker environmental 
legislation and enforcement. So, the trade agreements 
represent also a transfer of health risks to other nations, 
contributing to health inequalities around the world.
For these reasons, and more specific others, not 
discussed in this article, the final document of the 14th 
Congress of Public Health points that: “Trade agree-
ments form an important part of political and economic 
context for the social determinants of health and have 
significant effects on health and health equity” (14th 
Congress of Public Health, Kolkata, India, 2015). 
I agree with the social movements that these treaties 
should not be negotiated in secret, with the participation 
of more than 600 large corporations, but without Congress 
or the public, as they have been until now. They must be 
openly discussed and negotiated, as their health impacts 
are very complex and not fully understood. It should be 
given voice to all actors to work together as partners to 
attain global health equity. It is also time for Brazilian 
Public Health professionals to take part in this discussion.
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